MIZUHO MEDY CO.,LTD.

4595 株式会社ミズホメディー

Drug Manufacturers - Specialty & Generic · Standard · TSE: Disclosed

PRICE: ¥1,682 · MKT CAP: ¥32.0B · P/E: 9.4x · P/B: 1.71x · DIV YIELD: 5.9%

PRICE — 5Y

Characteristics & Business Summary

Mizuho Medy Co.,Ltd. engages in the research and development, manufacture, and sale of in vitro diagnostic products, and related scientific and technical information services in Japan. The company offers molecular diagnostic products, such as nucleic acid...

Income Statement Highlights (¥ Million, except EPS/DPS in ¥)

Fiscal Period	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Net Sales	13,137	17,582	10,990	11,429	11,260
Operating Profit	6,698	11,104	5,152	4,917	4,646
Ordinary Profit	6,700	11,071	5,292	5,167	4,736
Net Profit	4,817	7,838	3,774	3,773	3,425
EPS	¥506	¥823	¥396	¥198	¥180
DPS	¥155	¥250	¥200	¥140	¥100

Balance Sheet & Valuation Highlights

Total Assets ¥22B

Net Assets (Equity) ¥19B

Equity Ratio 83.5%

ROE (Return on Equity) 18.3%

Cash & Equivalents ¥11B

Interest-Bearing Debt ¥0B

Capital Expenditure (CapEx) ¥0B

Depreciation & Amort. ¥0B

Major Shareholders

1. 唐川文成 20.5%
2. ミズホメディー社員持株会 2.2%
3. 株式会社西日本シティ銀行 2.1%
4. 三菱UFJeスマート証券株式会社 1.6%
5. BNY GCM CLIENT ACCOUNT JPRD AC ISG (FE-AC)（常任代理人株式会社三菱UFJ銀行） 1.4%
6. BNY Mellon (Nominee) 1.3%
7. Morgan Stanley 1.2%
8. 山口和也 1.1%
9. 村田淳一 1.1%
10. 唐川則康 1.0%

Activist Activity

Fuminari Karakawa 20.99%

2025-01-06 · change

Fuminari Karakawa 22.96%

2024-12-10 · change

Historical Per-Share Data & Valuation Ratios

Per Share Metric	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenues per share	¥1,379	¥1,846	¥1,154	¥600	¥591
FCF/Share	¥571	¥629	¥391	¥160	¥89
EPS	¥506	¥823	¥396	¥198	¥180
DPS	¥155	¥250	¥200	¥140	¥100
Capital Spending per share	¥16	¥19	¥28	¥16	¥13
Book Value per share	¥843	¥1,499	¥1,646	¥911	¥981
Common Shares Outstanding	10M	10M	10M	19M	19M

Financial Aggregates & Margins

Financial Aggregate	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Revenues (Net Sales)	¥13B	¥18B	¥11B	¥11B	¥11B
Operating Margin (%)	51.0%	63.2%	46.9%	43.0%	41.3%
Net Profit (owners)	¥5B	¥8B	¥4B	¥4B	¥3B
Net Profit Margin (%)	36.7%	44.6%	34.3%	33.0%	30.4%
Working Capital	¥5B	¥12B	¥13B	¥15B	¥16B
Total Debt (Interest-bearing)	¥0B	¥0B	¥0B	¥0B	¥0B
Net Worth (Common Equity)	¥8B	¥14B	¥16B	¥17B	¥19B
Return on Total Assets (ROA)	39.5%	41.0%	19.9%	18.2%	15.3%
Return on Common Equity (ROE)	60.0%	54.9%	24.1%	21.7%	18.3%

Business Summary & Analysis

Capital Strategy Targets

No active capital policy disclosure records found.